JOINT VENTURE (Details Narrative) - USD ($)		1 Months Ended			9 Months Ended	12 Months Ended
	Apr. 02, 2022	Jul. 25, 2023	May 17, 2022	May 31, 2021	Mar. 31, 2024	Jun. 30, 2023
Description of Movychem's non-performance					Xeriant ceased paying Movychem $25,000 per month as provided in the Joint Venture beginning December 2022
XTI JV [Member]
Ownership owned percentage				50.00%
Financial commitment agreegate amount				$ 10,000,000
Initial Deposit				1,000,000
Diluted equity interest			6.00%
Principal balance of the note and warrant			$ 6,050,000.00
Investment obligation				$ 10,000,000
Description of merger agreement		Inpixon filed an 8-K, announcing their intention to merge with XTI having executed an Agreement of Plan and Merger with XTI. The filing also showed that XTI had engaged in a transaction with Inpixon on March 10, 2023, receiving $300,000 in funding. Inpixon filed an S-4 registration statement on August 14, 2023
Description of recovery of losses					These include the recovery of losses, expenses, attorneys’ fees, punitive damages and a compensatory damage award exceeding $500 million
Ebenberg LLC [Member]
Impairment of investment						$ 156,460
Joint Venture With Movychem [Member]
Ownership owned percentage	50.00%
Contribution amount						$ 312,919
Description about intellectual property	Movychem would transfer to the Joint Venture all of its interest to the know-how and intellectual property relating to Retacell® exclusive of all patents, and the Company would contribute the amount of $2,600,000 payable (a) $600,000 at the rate of $25,000 per month over a 24 month period and (b) $2,000,000 within five business days of a closing of a financing in which the Company receives net proceeds of at least $3,000,000 but in no event later than six months from the Effective Date
Company payment	$ 2,000,000
Purchase number of share common stock	170,000,000
Exercise price	$ 0.01